BC Innovations | Dec 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer; lung cancer Cell culture and mouse studies suggest inhibiting GSK3 could help treat KRAS-driven pancreatic, colon and lung cancers. Screening of a library of 304 kinase inhibitors in cell-based growth...
BC Week In Review | Mar 30, 2018
Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02) was generally well tolerated with...
BC Innovations | Mar 20, 2018
Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro , cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in vitro...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment,...
BC Innovations | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Glycogen dependent kinase 3 (GSK3); dyskerin pseudouridine synthase 1 (DKC1)

Other INDICATION: Dyskeratosis congenita Patient sample and cell culture studies suggest GSK3 inhibitors could help treat dyskeratosis congenita, which is caused by mutations in DKC1 or other genes that result in shortened telomeres, dysfunction in...
BC Week In Review | Aug 22, 2016
Clinical News

Tideglusib: Phase II started

AMO began a single-blind, placebo-controlled, U.K. Phase II trial to evaluate 400 and 1,000 mg oral tideglusib for 14 weeks in up to 16 patients ages 12-45. AMO licensed rights to tideglusib from Noscira. AMO...
BC Innovations | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22- LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels...
BC Extra | Oct 1, 2015
Financial News

Woodford backs AMO in $25M series A round

AMO Pharma Ltd. (London, U.K.) raised $25 million in a series A round from Woodford Investment Management through its Woodford Patient Capital Trust plc (LSE:WPCT) fund. AMO plans to begin Phase I/IIa testing next year...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
BC Week In Review | Oct 15, 2012
Clinical News

Tideglusib: Phase IIb data

The double-blind, European Phase IIb ARGO trial in 306 patients with mild to moderate AD showed that tideglusib missed the primary endpoint of improving ADAS-Cog score from baseline to week 26 vs. placebo. Noscira also...
Items per page:
1 - 10 of 28
BC Innovations | Dec 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer; lung cancer Cell culture and mouse studies suggest inhibiting GSK3 could help treat KRAS-driven pancreatic, colon and lung cancers. Screening of a library of 304 kinase inhibitors in cell-based growth...
BC Week In Review | Mar 30, 2018
Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02) was generally well tolerated with...
BC Innovations | Mar 20, 2018
Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro , cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in vitro...
BC Innovations | Oct 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment,...
BC Innovations | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Glycogen dependent kinase 3 (GSK3); dyskerin pseudouridine synthase 1 (DKC1)

Other INDICATION: Dyskeratosis congenita Patient sample and cell culture studies suggest GSK3 inhibitors could help treat dyskeratosis congenita, which is caused by mutations in DKC1 or other genes that result in shortened telomeres, dysfunction in...
BC Week In Review | Aug 22, 2016
Clinical News

Tideglusib: Phase II started

AMO began a single-blind, placebo-controlled, U.K. Phase II trial to evaluate 400 and 1,000 mg oral tideglusib for 14 weeks in up to 16 patients ages 12-45. AMO licensed rights to tideglusib from Noscira. AMO...
BC Innovations | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22- LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels...
BC Extra | Oct 1, 2015
Financial News

Woodford backs AMO in $25M series A round

AMO Pharma Ltd. (London, U.K.) raised $25 million in a series A round from Woodford Investment Management through its Woodford Patient Capital Trust plc (LSE:WPCT) fund. AMO plans to begin Phase I/IIa testing next year...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
BC Week In Review | Oct 15, 2012
Clinical News

Tideglusib: Phase IIb data

The double-blind, European Phase IIb ARGO trial in 306 patients with mild to moderate AD showed that tideglusib missed the primary endpoint of improving ADAS-Cog score from baseline to week 26 vs. placebo. Noscira also...
Items per page:
1 - 10 of 28